TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
USA - NYSE:TEVA - US8816242098 - ADR
24.44 USD
-0.4 (-1.61%)
24.43 USD
-0.01 (-0.04%)
We assign a fundamental rating of 4 out of 10 to TEVA. TEVA was compared to 192 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of TEVA while its profitability can be described as average. TEVA has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
TEVA had positive earnings in the past year.
TEVA had a positive operating cash flow in the past year.
TEVA had negative earnings in 4 of the past 5 years.
TEVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
TEVA has a better Return On Assets (-0.39%) than 78.13% of its industry peers.
TEVA has a better Return On Equity (-2.31%) than 78.13% of its industry peers.
The Return On Invested Capital of TEVA (10.49%) is better than 90.10% of its industry peers.
TEVA had an Average Return On Invested Capital over the past 3 years of 9.12%. This is below the industry average of 13.48%.
The 3 year average ROIC (9.12%) for TEVA is below the current ROIC(10.49%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROIC | 10.49% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
TEVA has a better Operating Margin (22.59%) than 89.06% of its industry peers.
TEVA's Operating Margin has improved in the last couple of years.
TEVA has a better Gross Margin (50.88%) than 63.54% of its industry peers.
TEVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, TEVA has more shares outstanding
The number of shares outstanding for TEVA has been increased compared to 5 years ago.
Compared to 1 year ago, TEVA has an improved debt to assets ratio.
2.2 Solvency
TEVA has an Altman-Z score of 0.74. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
TEVA has a Altman-Z score (0.74) which is in line with its industry peers.
The Debt to FCF ratio of TEVA is 19.36, which is on the high side as it means it would take TEVA, 19.36 years of fcf income to pay off all of its debts.
TEVA has a better Debt to FCF ratio (19.36) than 75.00% of its industry peers.
A Debt/Equity ratio of 2.46 is on the high side and indicates that TEVA has dependencies on debt financing.
With a Debt to Equity ratio value of 2.46, TEVA is not doing good in the industry: 79.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Altman-Z | 0.74 |
ROIC/WACC1.31
WACC7.98%
2.3 Liquidity
TEVA has a Current Ratio of 1.06. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.06, TEVA is doing worse than 81.25% of the companies in the same industry.
A Quick Ratio of 0.77 indicates that TEVA may have some problems paying its short term obligations.
TEVA has a Quick ratio of 0.77. This is amonst the worse of the industry: TEVA underperforms 84.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
The earnings per share for TEVA have decreased by -3.96% in the last year.
TEVA shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.18% yearly.
TEVA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.40%.
Measured over the past years, TEVA shows a decrease in Revenue. The Revenue has been decreasing by -0.41% on average per year.
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)4.4%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
3.2 Future
TEVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.25% yearly.
The Revenue is expected to grow by 1.77% on average over the next years.
EPS Next Y5.48%
EPS Next 2Y6.39%
EPS Next 3Y8.25%
EPS Next 5YN/A
Revenue Next Year2.79%
Revenue Next 2Y1.59%
Revenue Next 3Y1.77%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.05, the valuation of TEVA can be described as very reasonable.
91.15% of the companies in the same industry are more expensive than TEVA, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of TEVA to the average of the S&P500 Index (25.47), we can say TEVA is valued rather cheaply.
With a Price/Forward Earnings ratio of 8.57, the valuation of TEVA can be described as very reasonable.
Based on the Price/Forward Earnings ratio, TEVA is valued cheaper than 89.06% of the companies in the same industry.
TEVA's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.05 | ||
| Fwd PE | 8.57 |
4.2 Price Multiples
TEVA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TEVA is cheaper than 90.10% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TEVA is valued a bit cheaper than the industry average as 79.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.5 | ||
| EV/EBITDA | 9.01 |
4.3 Compensation for Growth
TEVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of TEVA may justify a higher PE ratio.
PEG (NY)1.65
PEG (5Y)N/A
EPS Next 2Y6.39%
EPS Next 3Y8.25%
5. Dividend
5.1 Amount
No dividends for TEVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.44
-0.4 (-1.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.48%
Inst Owner Change-9.69%
Ins Owners0.43%
Ins Owner Change0.83%
Market Cap28.04B
Revenue(TTM)16.54B
Net Income(TTM)-158.00M
Analysts42.22
Price Target0.06 (-99.75%)
Short Float %4.49%
Short Ratio4.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.24%
Min EPS beat(2)4.65%
Max EPS beat(2)5.84%
EPS beat(4)4
Avg EPS beat(4)3.88%
Min EPS beat(4)2.01%
Max EPS beat(4)5.84%
EPS beat(8)6
Avg EPS beat(8)4.79%
EPS beat(12)7
Avg EPS beat(12)-0.36%
EPS beat(16)9
Avg EPS beat(16)-0.6%
Revenue beat(2)0
Avg Revenue beat(2)-4.72%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)-4.68%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)2.63%
Revenue beat(8)5
Avg Revenue beat(8)0.64%
Revenue beat(12)6
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-1.7%
PT rev (1m)4.61%
PT rev (3m)3.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.91%
EPS NY rev (1m)0%
EPS NY rev (3m)2.84%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-1.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.05 | ||
| Fwd PE | 8.57 | ||
| P/S | 1.69 | ||
| P/FCF | 31.5 | ||
| P/OCF | 20.17 | ||
| P/B | 4.11 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.01 |
EPS(TTM)2.7
EY11.05%
EPS(NY)2.85
Fwd EY11.67%
FCF(TTM)0.78
FCFY3.17%
OCF(TTM)1.21
OCFY4.96%
SpS14.5
BVpS5.95
TBVpS-11.56
PEG (NY)1.65
PEG (5Y)N/A
Graham Number19.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROCE | 13.29% | ||
| ROIC | 10.49% | ||
| ROICexc | 11.36% | ||
| ROICexgc | 49.13% | ||
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% | ||
| FCFM | 5.35% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexgc growth 3Y25.78%
ROICexgc growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score6
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Debt/EBITDA | 3.51 | ||
| Cap/Depr | 48.92% | ||
| Cap/Sales | 3.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 29.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 0.74 |
F-Score6
WACC7.98%
ROIC/WACC1.31
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y5.48%
EPS Next 2Y6.39%
EPS Next 3Y8.25%
EPS Next 5YN/A
Revenue 1Y (TTM)4.4%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
Revenue Next Year2.79%
Revenue Next 2Y1.59%
Revenue Next 3Y1.77%
Revenue Next 5YN/A
EBIT growth 1Y1.19%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year17.17%
EBIT Next 3Y7.55%
EBIT Next 5YN/A
FCF growth 1Y-24.19%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-18.04%
OCF growth 3Y16.04%
OCF growth 5Y10.76%
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the fundamental rating for TEVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
What is the valuation status for TEVA stock?
ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 6 / 10.
What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 9.05 and the Price/Book (PB) ratio is 4.11.
What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.